Skip to main content
SpringerLink
Log in

Radiotherapie mit Cetuximab oder Cisplatin beim Plattenepithelkarzinom der Kopf-Hals-Region – was ist zu bevorzugen?

Radiotherapy with cetuximab or cisplatin for squamous cell carcinoma of the head and neck—what should be preferred?

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Adelstein DJ, Li Y, Adams GL, Wagner H Jr., Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1):92–98. https://doi.org/10.1200/JCO.2003.01.008

    Article  PubMed  Google Scholar 

  2. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578. https://doi.org/10.1056/NEJMoa053422

    Article  CAS  PubMed  Google Scholar 

  3. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28. https://doi.org/10.1016/S1470-2045(09)70311-0

    Article  CAS  PubMed  Google Scholar 

  4. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589. https://doi.org/10.1200/JCO.2007.14.8841

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393(10166):40–50. https://doi.org/10.1016/S0140-6736(18)32779-X

    Article  CAS  PubMed  Google Scholar 

  6. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. https://doi.org/10.1056/NEJMoa0912217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O’Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J, De EHPVTG (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393(10166):51–60. https://doi.org/10.1016/S0140-6736(18)32752-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA (2016) Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J Clin Oncol 34(12):1300–1308. https://doi.org/10.1200/JCO.2015.62.5970

    Article  CAS  PubMed  Google Scholar 

  9. Riaz N, Sherman E, Koutcher L, Shapiro L, Katabi N, Zhang Z, Shi W, Fury M, Wong R, Wolden S, Rao S, Lee N (2016) Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol 39(1):27–31. https://doi.org/10.1097/COC.0000000000000006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesia R, Zhang A, Oliner KS, VanderWalde A (2015) Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16(2):221–232. https://doi.org/10.1016/S1470-2045(14)71200-8

    Article  CAS  PubMed  Google Scholar 

  11. Magrini SM, Buglione M, Corvo R, Pirtoli L, Paiar F, Ponticelli P, Petrucci A, Bacigalupo A, Crociani M, Lastrucci L, Vecchio S, Bonomo P, Pasinetti N, Triggiani L, Cavagnini R, Costa L, Tonoli S, Maddalo M, Grisanti S (2016) Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol 34(5):427–435. https://doi.org/10.1200/JCO.2015.63.1671

    Article  CAS  PubMed  Google Scholar 

  12. Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, Beron P, Wong D, Rosove MH, Rao S, Melanson H, Kim E, Palmer D, Qi L, Kelly K, Steinberg ML, Kupelian PA, Daly ME (2017) Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol 18(6):803–811. https://doi.org/10.1016/S1470-2045(17)30246-2

    Article  PubMed  PubMed Central  Google Scholar 

  13. National Comrehensive Cancer Network Guideline for head and neck cancers (version 2.2019, 06/28/19). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Zugegriffen: 2. Aug. 2019

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie und Onkologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland

    Jens von der Grün

  2. Klinik für Radio-Onkologie, Universitätsspital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz

    Panagiotis Balermpas

Authors
  1. Jens von der Grün
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panagiotis Balermpas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jens von der Grün or Panagiotis Balermpas.

Ethics declarations

Interessenkonflikt

J. von der Grün und P. Balermpas geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Bauml JM, Vinnakota R, Anna Park YH et al (2019) Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: an analysis of veterans health affairs data. Cancer 125(3):406–415, https://doi.org/10.1002/cncr.31816.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

von der Grün, J., Balermpas, P. Radiotherapie mit Cetuximab oder Cisplatin beim Plattenepithelkarzinom der Kopf-Hals-Region – was ist zu bevorzugen?. Strahlenther Onkol 196, 197–199 (2020). https://doi.org/10.1007/s00066-019-01568-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01568-w

Search

Navigation